Losartan improves diastolic ventricular filling of hypertensive patients with diastolic dysfunction

Hypertension Research - Clinical and Experimental

Volumn 22, Issue 2, 1999, Pages 155-159

  Ayoub, José C A ^a  

^a Instituto de Molestias Cardiovasculares   (Brazil)

Author keywords

Angiotensin II antagonists; Diastolic dysfunction; Losartan

Indexed keywords

ANGIOTENSIN II ANTAGONIST; LOSARTAN POTASSIUM;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE MASS; HEART VENTRICLE FILLING; HUMAN; HYPERTENSION; MALE; RADIOISOTOPE VENTRICULOGRAPHY; SYMPTOM;

EID: 0032772598     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.22.155     Document Type: Conference Paper

References (27)

1. Fouad FM, Slominski JM, Tarazi RC: Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol 1984; 3: 1500-1506.
2. Liu Y, Leri A, Li B, et al: Angiotensin II stimulation in vitro induces hypertrophy of normal and post-infarcted ventricular myocytes. Circ Res 1998; 82: 1145-1159.
3. Dahlof B. The importance of the renin-angiotensin system in reversal of left ventricular hypertrophy. J Hypertens Suppl 1993; 11 (3): S29-S35.
4. Brilla CG, Rupp H, Funck R, Maisch B: The reninangiotensin-aldorestorone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J 1995; 16 (Suppl O): 107-109.
5. Brilla CG, Scheer C, Rupp H: Renin-angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism. J Hypertens Suppl 1997; 15 (6): S13-S19.
6. Wilke A, Funck R, Rupp H, Brilla CG: Effect of renin-angiotensin-aldosterone system on the cardiac interstitium in heart failure. Basic Res Cardiol 1996; 91 (Suppl 2): 79-84.
7. Lorell BH, Schunkert H: Induction of the cardiac angiotensin converting enzyme in pressure-overload hypertrophy: implications for diastolic function, in Lindpaintner K, Ganten D (eds): The cardiac reninangiotensin system. Armonk, Futura, 1994, pp!83199.
8. Urata H, Boehm K, Philip A, et al: Human chymase: ' cellular localization and regional distribution of a major angiotensin II-forming enzyme in the heart. J Clin Invest 1993; 91: 1269-1280.
9. Cheng CP, Suzuki M, Ohte N, Ohno M, Wang ZM, Little WC: Altered ventricular and myocyte response to angiotensin II in pacing-induced heart failure. Circ Res 1996; 78: 880-892.
10. Ju H, Zhao S, Jassal DS, Dixon IM: Effect of A^ receptor blockade on cardiac collagen remodeling after myocardial infarction. Cardiovasc Res 1997; 35: 223-232.
11. Pitt B, Segal R, Martinez FA, et al: Randomized trial of losartan versus captopril in patients over 65 with heart failure. Lancet 1997; 349: 747-752.
12. Waeber B, Nussberger J, Brunner HR: Angiotensinconverting enzyme inhibitors in hypertension, in Laragh JH, Brenner BM (eds): Hypertension: pathophysiology, diagnosis and management, 2nd ed. New York, Raven Press, 1995; pp2861-2872.
13. Smith VE, White WB, Meeran MK, Karimeddini MK: Improved left ventricular filling accompanies reduced left ventricular mass during therapy of essential hypertension. J Am Coll Cardiol 1986; 8: 1449-1454.
14. Schulman SP, Weiss JL, Decker LC, et al: The effects of antihypertensive therapy on left ventricular mass in elderly patients. N Engl J Med 1990; 322: 1350-1356.
15. Troy BL, Pombo J, Rackley CE: Measurement of left ventricular wall thickness and mass by echocardiography. Circulation 1972; 45: 602-611.
16. Johnson LL, Pohost GM: Nuclear Cardiology, in Schlant RC, Wayne R (eds): Em Hum's The Heart. 8th ed., Alexander, 1994, pp2281-2323.
17. Douherty AH, Nacarelli GV, Gray EL, Hicks CH, Goldstein RA: Congestive heart failure with normal systolic function. Am J Cardiol 1984; 54: 778-782.
18. Iriarte M, Murga N, Sagastagoitia D, et al: Congestive heart failure from left ventricular diastolic dysfunction in systemic hypertension. Am J Cardiol 1993; 71: 308-312.
19. Cuocolo A, Sax FL, Brush JE, Maron BJ, Bacharach SL, Bonow RO: Left ventricular hypertrophy and impared diastolic filling in essential hypertension. Circulation 1990; 81: 978-986.
20. Johnston CI: Angiotensin converting enzyme inhibition, in Robertson JIS, Nichols MG (eds): The renin angiotensin system. London, Gower Medical Publications, 1993, pp87.1-87.15.
21. Chiu AT, Mcmall DE, Price WA, et ai. Non-Peptide angiotensin II receptor antagonists: VII. Cellular and biochemical pharmacology of Dup 753, an orally active antihypertensive agent. J Pharmacol Exp Ther 1990; 252: 711-718.
22. Smith RD, Chiu AT, Wong PC, et al: Pharmacology of non-peptide angiotensin II receptor antagonists. Annu Rev Pharmacol Toxicol 1992; 32: 135-165.
23. Sweet CS, Rucinska EJ: Losartan in heart failure: preclinical experiences and initial outcomes. Eur Heart J 1994; 15 (D): 1139-1144.
24. Pitt B, Chang P, Timmermans PB: Angiotensin II receptor antagonists in heart failure: rational and design of the evaluation of losartan in the elderly (ELITE) trial. Cardiovasc Drugs Ther 1995; 9: 693700.
25. Qing G, Garcia R: Chronic captopril and losartan (DuP 753) administration in rats with high-output heart failure. Am J Physiol 1992; 263 (3 Pt 2): H833H840.
26. Liu YH, Yng XP, Sharov VG, et ah Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure: role of kinins and angiotensin II type 2 receptors. J Clin Invest 1997; 99: 1926-1935.
27. Inouye I, Massie B, Loge D, et ah Abnormal left ventricular filling: an early finding in mild to moderate hypertension. Am J Cardiol 1984; 53: 120-126.